(153 days)
Vision 2, TrackVision 2 and HeartVision 2 software applications are intended to enable users to load 3D datasets and overlay and register in real time these 3D datasets with radioscopic or radiographic images of the same anatomy in order to support catheter/device guidance during interventional procedures.
The Stereo 3D option enables physicians to visualize needles, points, and segments on a 3D model/space using a stereotaction of radioscopic or radiographic images at a significantly lower dose than use of a full cone beam CT acquisition. This information is intended to assist the physician during interventional procedures.
Vision Applications (K092639) includes Vision 2, TrackVision 2 and HeartVision 2 applications. Vision Applications can load and dynamically fuse in real-time live 2D X-ray images from the X-ray system with 3D models from X-Ray (DICOM 3D XA), CT or MR system.
Stereo 3D is a new option and the subject of this submission. The Stereo 3D option is designed to be used with the Vision 2 and TrackVision 2 applications which are part of Vision Applications. The Stereo 3D option enables the user to reconstruct 3D objects from radioscopic or radiographic images.
The Stereo 3D option intends to provide an alternative to intra operative CBCT (cone beam CT) usually performed for the same purpose: to localize needles and markers within the 3D anatomy. The Stereo 3D option provides a method to reconstruct 3D contrasted objects (point and segments) from a pair of 2D X-ray images, e.g. acquisition of fluoroscopic images from different C-arm positions (2 different projections). The 3D object reconstruction is then fused in the 3D space with the 3D model used at the fusion of the x-ray image.
Stereo 3D has a workflow that is significantly guided, to support clear and easy use of the reconstruction procedure. The workflow contains the following 4 high level steps:
Image acquisition and registration adjustment
Automatic or manual object identification
Quality assessment of 3D reconstruction
Display of the reconstructed point(s) and segment(s) on a cross section of the 3D model.
The second step (object identification) can be done manually or automatically:
Manual point(s) or segment(s) identification:
After the acquisition and registration of the two x-ray images acquired at two different C-arm positions, the user has to manually select points on the two x-ray images which correspond to the object to reconstruct (e.g. endograph markers and needles).
Automatic Mode for needles (only with Trackvision 2):
The user first selects a planned trajectory with a needle inserted
After the acquisition of the two X-ray images, and the registration adjustment phase, the needle will automatically be detected and reconstructed.
The provided document refers to the "Stereo 3D option for Vision Applications" (K152352). This device is an enhancement to existing GE Vision Applications (Vision 2, TrackVision 2, and HeartVision 2) and aims to reconstruct 3D objects (needles, points, and segments) from 2D X-ray images.
Based on the provided text, the device did not involve a study to establish acceptance criteria for its performance in terms of diagnostic accuracy or reader improvement. Instead, the submission relies on non-clinical tests to demonstrate substantial equivalence to predicate devices and adherence to relevant standards.
Here's a breakdown of the requested information based on the provided text:
1. Table of Acceptance Criteria and Reported Device Performance
The document does not explicitly state quantitative acceptance criteria for device performance in terms of accuracy or clinical effectiveness for the Stereo 3D option. Instead, it focuses on demonstrating compliance with standards and successful completion of various engineering and usability tests.
| Acceptance Criteria (Implied) | Reported Device Performance |
|---|---|
| Compliance with NEMA PS 3.1 - 3.20 (2011) DICOM Set | "The Stereo 3D option for Vision Applications comply with NEMA PS 3.1 - 3.20 (2011) Digital Imaging and Communications in Medicine (DICOM) Set..." |
| Compliance with IEC 62304 (2006) (Software Lifecycle Processes) | "...and with voluntary standards IEC 62304 (2006) and IEC 62366 (2007)." (Implies successful adherence to software development and risk management for medical devices) |
| Compliance with IEC 62366 (2007) (Usability) | "Usability validation testing is conducted to confirm that the product can be used safely and effectively." (Reported as completed and successful, with no unexpected results.) |
| Software Verification (conformance to requirements) | "Product verification ensures the software conforms to its requirements including hazard mitigations risk management requirements. The verification tests confirmed that design output meets design input requirements. The tests were executed at component, software subsystems, and system levels. Functional testing and performance testing are part of system level verification." (Reported as completed and successful) |
| Performance Confirmation (bench testing) | "Performance has been confirmed with bench testing." and "Additional bench testing was performed to substantiate Stereo 3D's product claims." and "engineering bench testing was able to be performed using existing phantoms, methods, and performance metrics. The requirements were met and there were not any unexpected results." (Reported as completed and successful, substantiating claims.) |
| Simulated Use Testing (conformance to user needs/intended uses) | "Simulated Use Testing ensured the system conforms to user needs and intended uses through simulated clinical workflows using step-by step procedures that would be performed for representative clinical applications." (Reported as completed and successful, with no unexpected results.) |
| Hazard Mitigation | "All causes of hazard relative to the introduction of Stereo 3D option have been identified and mitigated." and "Verification and Validation testing has demonstrated that the design inputs, user requirements, and risk mitigations have been met." (Reported as adequately addressed.) |
| No new issues of safety and effectiveness | "The results of design validation did not raise new issues of safety and effectiveness." and "The Stereo 3D Option for Vision Applications does not raise new issues of safety and effectiveness. The Stereo 3D Option for Vision Applications does not introduce new fundamental scientific technology." (Conclusion of the submission, implying this criterion was met through the various non-clinical tests and substantial equivalence argument.) |
2. Sample size used for the test set and the data provenance
The document explicitly states: "The Stereo 3D option for Vision Applications did not require clinical studies to assess safety and effectiveness and, thus, to establish the substantial equivalence."
Therefore, there is no mention of a "test set" in the context of clinical data, sample size, or data provenance (country of origin, retrospective/prospective). The assessment was based on non-clinical testing, including "bench testing" and "simulated clinical workflows using step-by-step procedures."
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
Not applicable, as no clinical test set with human expert ground truth was used for assessing the device's performance. The "usability validation testing" involved "licensed and/or clinically trained healthcare providers or users," but this was for confirming usability, not establishing ground truth for reconstructive accuracy.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
Not applicable, as no clinical test set necessitating adjudication was used.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
No MRMC comparative effectiveness study was done. The submission explicitly states no clinical studies were required.
6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done
The document mentions "bench testing" and "performance testing" to confirm the device's functionality and "substantiate Stereo 3D's product claims." It also notes: "Stereo 3D contains the algorithms used to detect the 2D needles on the image and to reconstruct points, needles and segments in 3D from fluoroscopic images." This implies that the algorithms themselves were tested, which can be seen as a form of standalone testing in a controlled, non-clinical environment (e.g., using phantoms). However, specific metrics of standalone algorithmic performance (e.g., accuracy of 3D reconstruction against synthetic ground truth) or detailed study designs for this have not been provided beyond general statements about "performance being confirmed."
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)
For the non-clinical "bench testing" and "performance testing," the ground truth likely involved phantom data with known 3D object positions and measurements. The document states: "engineering bench testing was able to be performed using existing phantoms, methods, and performance metrics."
8. The sample size for the training set
The document does not mention a "training set" in the context of machine learning or AI models with a large dataset. The "Stereo 3D option" is described as containing "algorithms used to detect the 2D needles... and to reconstruct points, needles and segments in 3D." It is based on "established GE technology" and the 3D reconstruction technology of an earlier predicate device ("Innova 3D"). This suggests that if there was any "training" in a modern AI sense, it happened as part of the development of the underlying algorithms, which are considered "established technology," and no specific training set size or methodology is provided for this submission.
9. How the ground truth for the training set was established
Not applicable, as no "training set" in a modern AI context is described or detailed for this submission. The technology is based on "established GE technology," implying algorithms developed and potentially validated previously, likely using phantom data or engineered models to establish ground truth for calibration and development of reconstruction techniques.
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a symbol that appears to be three stylized human profiles facing to the right.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
January 20, 2016
GE Medical Systems, SCS % Mr. John Jaeckle Regulatory Affairs Leader 283 rue de la MINIERE Buc 78530 FRANCE
Re: K152352
Trade/Device Name: Stereo 3D option for Vision Applications Regulation Number: 21 CFR 892.2050 Regulation Name: Picture archiving and communications system Regulatory Class: II Product Code: LLZ, OWB Dated: December 11, 2015 Received: December 14, 2015
Dear Mr. Jaeckle:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{1}------------------------------------------------
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Robert Oolo
Robert Ochs, Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K152352
Device Name Stereo 3D option for Vision Applications
Indications for Use (Describe)
Vision 2, TrackVision 2 and HeartVision 2 software applications are intended to enable users to load 3D datasets and overlay and register in real time these 3D datasets with radioscopic or radiographic images of the same anatomy in order to support catheter/device guidance during interventional procedures.
The Stereo 3D option enables physicians to visualize needles, points, and segments on a 3D model/space using a stereotaction of radioscopic or radiographic images at a significantly lower dose than use of a full cone beam CT acquisition. This information is intended to assist the physician during interventional procedures.
Type of Use (Select one or both, as applicable)
| Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
|---|---|
| -------------------------------------------------------------------------- | --------------------------------------------- |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
Image /page/3/Picture/1 description: The image shows the General Electric (GE) logo. The logo consists of the letters "GE" in a stylized script, enclosed within a blue circle. The circle is surrounded by a series of white, wave-like shapes, giving the impression of motion or energy emanating from the center.
510(k) Summary
In accordance with 21 CFR 807.92 the following summary of information is provided:
| Date: | 11-December-2015 |
|---|---|
| Submitter: | GE Healthcare, (GE Medical Systems SCS)283 rue de la MINIERE78530 Buc, France |
| Primary ContactPerson: | Ning WENRegulatory Affairs LeaderGE Healthcare, (GE Medical Systems SCS)Tel: (+33)-1-3070-5668Email: ning.wen@ge.com |
| Secondary ContactPersons: | Michel GENUERRegulatory Affairs Program ManagerGE Healthcare, (GE Medical Systems SCS)Tel: (+33)-1-3070-4741Email: michel.genuer@ge.comJohn JaeckleChief Regulatory Affairs StrategistGE HealthcareTel: (262) 424-9547Email: John.Jaeckle@ge.com |
| Device Trade Name: | Stereo 3D option for Vision Applications |
| Common/Usual Name: | Stereo 3D option for Vision Applications |
| Classification Names: | Picture archiving and communications systemImage-intensified fluoroscopic x-ray system |
| Product Code: | LLZ - 21CFR 892.2050OWB - 21CFR 892.1650 |
| Class: | II |
| Primary PredicateDevice(s): | K092639, Innova Vision Applications (from GE Healthcare)Product code: LLZ; Regulation number: 892.2050. |
| Second PredicateDevice(s): | K052412, Innova 3D (from GE Healthcare)Product code: OWB, JAA; Regulation number : 892.1650. |
| Device Description: | Vision Applications (K092639) includes Vision 2, TrackVision 2 and HeartVision 2 applications. Vision Applications can load and dynamically fuse in real-time live 2D X-ray images from the X-ray system with 3D models from X-Ray (DICOM 3D XA), CT or MR system.Stereo 3D is a new option and the subject of this submission. The Stereo 3D option is designed to be used with the Vision 2 and TrackVision 2 applications which are part of Vision Applications. The Stereo 3D option enables the user to reconstruct 3D objects from radioscopic or radiographic images.The Stereo 3D option intends to provide an alternative to intra operative CBCT (cone beam CT) usually performed for the same purpose: to localize needles and markers within the 3D anatomy. The Stereo 3D option provides a method to reconstruct 3D contrasted objects (point and segments) from a pair of 2D X-ray images, e.g. acquisition of fluoroscopic images from different C-arm positions (2 different projections). The 3D object reconstruction is then fused in the 3D space with the 3D model used at the fusion of the x-ray image.Stereo 3D has a workflow that is significantly guided, to support clear and easy use of the reconstruction procedure. The workflow contains the following 4 high level steps:Image acquisition and registration adjustment Automatic or manual object identification Quality assessment of 3D reconstruction Display of the reconstructed point(s) and segment(s) on a cross section of the 3D model. The second step (object identification) can be done manually or automatically:Manual point(s) or segment(s) identification:After the acquisition and registration of the two x-ray images acquired at two different C-arm positions, the user has to manually select points on the two x-ray images which correspond to the object to reconstruct (e.g. endograph markers and needles).Automatic Mode for needles (only with Trackvision 2):The user first selects a planned trajectory with a needle inserted |
| After the acquisition of the two X-ray images, and the registrationadjustment phase, the needle will automatically be detected andreconstructed. | |
| Intended Use: | Vision 2, TrackVision 2 and HeartVision 2 software applications areintended to enable users to load 3D datasets and overlay andregister in real time these 3D datasets with radioscopic orradiographic images of the same anatomy in order to supportcatheter/device guidance during interventional procedures. |
| Indication for Use: | Vision 2, TrackVision 2 and HeartVision 2 software applications areintended to enable users to load 3D datasets and overlay andregister in real time these 3D datasets with radioscopic orradiographic images of the same anatomy in order to supportcatheter/device guidance during interventional procedures. |
| The Stereo 3D option enables physicians to visualize and localizeneedles, points, and segments on a 3D model/space using astereotactic reconstruction of radioscopic or radiographic imagesat a significantly lower dose than use of a full cone beam CTacquisition. This information is intended to assist the physicianduring interventional procedures. | |
| Technology: | Vision Applications are software applications that execute on theAdvantage Workstation (AW) review workstation [K110834]. |
| The live fluoroscopic images, as well as the necessary exam data,are transmitted from the Interventional fluoroscopic X-ray systemto the AW through a dedicated link. The 3D datasets previouslyacquired (from XA only for TrackVision 2, and from XA, CT and MRfor Vision 2 and HeartVision 2) are loaded from the AW database. | |
| The 3D-2D fusion and the user interface of the application aredisplayed on the AW main screen, which is distributed identically inboth the Control and Exam Rooms, The most frequently usedfunctions are available from the Central Touch Screen at table sidein the exam room. This user interface is controlled by theapplication through the Interventional fluoroscopic X-ray systemEthernet network. | |
| The Vision Applications employ the same fundamental scientifictechnology as its primary predicate devices. | |
| The new Stereo 3D option is an embedded software component ofthe Vision 2 and/or TrackVision 2 components of VisionApplications. This option is designed to reconstruct 3D object(s).Stereo 3D contains the algorithms used to detect the 2D needleson the image and to reconstruct points, needles and segments in3D from fluoroscopic images. Stereo 3D option is based on the 3Dreconstruction technology of “Innova 3D” [K052412] that is secondpredicate device and also runs on AW platforms. | |
| The reconstructed 3D objects can be displayed by Vision Applications on the initial 3D model (fused with live 2D), and exported to Volume Viewer [K041521].All causes of hazard relative to the introduction of Stereo 3D option have been identified and mitigated. | |
| Determination of Substantial Equivalence: | The following testing was used to assess safety and effectiveness and, thus, to establish the substantial equivalence with the predicate devices. |
| Summary of Non-Clinical Tests: | |
| The Stereo 3D option for Vision Applications comply with NEMA PS 3.1 - 3.20 (2011) Digital Imaging and Communications in Medicine (DICOM) Set and with voluntary standards IEC 62304 (2006) and IEC 62366 (2007). | |
| The following quality management measures were applied to the development of the software application:Product verification ensures the software conforms to its requirements including hazard mitigations risk management requirements. The verification tests confirmed that design output meets design input requirements. The tests were executed at component, software subsystems, and system levels. Functional testing and performance testing are part of system level verification. Performance has been confirmed with bench testingSimulated Use Testing ensured the system conforms to user needs and intended uses through simulated clinical workflows using step-by step procedures that would be performed for representative clinical applications.Usability validation testing is conducted to confirm that the product can be used safely and effectively. The participants used for this testing were licensed and/or clinically trained healthcare providers or users.Additional bench testing was performed to substantiate Stereo 3D's product claims. | |
| Summary of Clinical Tests: | |
| The Stereo 3D option for Vision Applications did not require clinical studies to assess safety and effectiveness and, thus, to establish the substantial equivalence. | |
| Stereo 3D is based on established GE technology which enabled use of our "typical” verification and validation testing methods. Additionally, engineering bench testing was able to be performed using existing phantoms, methods, and performance metrics. The | |
| requirements were met and there were not any unexpected results. | |
| Conclusion: | GE Healthcare considers the Stereo 3D Option for Vision Applications to be as safe and as effective and substantially equivalent to the predicate devices. |
| This conclusion is based on:Verification and Validation testing has demonstrated that the design inputs, user requirements, and risk mitigations have been met. Bench testing has demonstrated the performance and substantiated the claims of Stereo 3D. The results of design validation did not raise new issues of safety and effectiveness. The successful completion of the above testing was sufficient to assess safety and effectiveness and, thus, to establish the substantial equivalence. The Stereo 3D Option for Vision Applications does not raise new issues of safety and effectiveness. The Stereo 3D Option for Vision Applications does not introduce new fundamental scientific technology. |
{4}------------------------------------------------
Image /page/4/Picture/0 description: The image shows the General Electric (GE) logo. The logo consists of the letters 'g' and 'e' intertwined in a stylized script, enclosed within a circular shape. The circular shape has four wave-like elements extending outward from the circle at the top, bottom, left, and right.
GE Healthcare 510(k) Premarket Notification Submission
{5}------------------------------------------------
Image /page/5/Picture/0 description: The image shows the General Electric (GE) logo. The logo consists of the letters 'GE' intertwined in a stylized script, enclosed within a circular frame. The color of the logo is a bright, vibrant blue.
GE Healthcare 510(k) Premarket Notification Submission
{6}------------------------------------------------
{7}------------------------------------------------
Image /page/7/Picture/0 description: The image shows the General Electric (GE) logo. The logo consists of the letters 'GE' in a stylized, cursive font, enclosed within a blue circle. The circle has decorative swirls or flourishes around the letters, giving it a classic and recognizable appearance. The logo is simple, yet distinctive, and is widely recognized as the symbol of the General Electric company.
GE Healthcare 510(k) Premarket Notification Submission
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).